Viking Therapeutics Stares Down a 2.5-Year Runway After a Quarter That Missed on the Bottom Line
Published on 10/29/2026 at 13:51 | Editorial boerse-global.de
Viking Therapeutics has given investors two very different numbers to chew on this week: a per-share loss that blew past Wall Street's estimates, and a timeline that pushes the commercial debut of its flagship obesity drug roughly 2.5 years into the future. Both landed during the company's earnings call, and together they frame the central question facing shareholders — how much capital will be burned before VK2735 ever reaches a pharmacy shelf.
CEO Brian Lian told analysts on the call that a potential market entry for VK2735 sits about 2.5 years away. That guidance matters because Viking now has four Phase 3 trials running across both the injectable and oral forms of the drug, meaning the story has moved past the simple milestone of entering late-stage testing. What counts now is execution across those programs. Lian's figure is an estimate, not a commitment.
Where the Pipeline Stands
The two subcutaneous studies, VANQUISH-1 and VANQUISH-2, are fully enrolled and expected to wrap up in 2027. The larger of the pair holds roughly 4,500 participants, with the second enrolling about 1,000, and both are running on schedule according to the company. First subjects are slated to roll into extension phases in early 2027.
Full enrollment is real progress, though it is a long way from completed trials or an approved product. For anyone valuing the equity, the clinical readouts will carry far more weight than recruitment status alone.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
Viking also recently kicked off the SUNRISE program, which adds an oral formulation to the injectable's development and will study VK2735 over 68 weeks. That lengthy window is a useful reminder that launching a Phase 3 program is not the same as approaching near-term sales.
Away from its lead asset, Viking is developing VK3019. The single-ascending-dose Phase 1 trial should finish in the fourth quarter of 2026, with a multiple-ascending-dose study penciled in for the first quarter of 2027. These give investors additional calendar markers to track rather than forcing them to fixate solely on the distant commercialization horizon.
The Cost of Running Four Late-Stage Trials at Once
The financials Lian presented paint a starker picture. Viking posted a net loss of $183.2 million for the third quarter of 2026, with no quarterly revenue booked. That loss came in at more than double the prior-year period. On a per-share basis, the shortfall was $1.55 against the $1.06 analysts had modeled.
Research and development spending climbed to $166.8 million, an 85.3% jump year over year, while general and administrative costs rose to $20.3 million. The overrun isn't confined to the clinic — the broader organization is consuming more cash too. Missing consensus by that margin shows the strain under the line ran deeper than the market had assumed.
Cash, Burn, and a Freshly Topped-Up Balance Sheet
As of the end of September, Viking reported cash, cash equivalents, and short-term investments of $960 million. Management expects an average cash burn of roughly $100 million per quarter, though the figure will fluctuate.
That projected burn should not be conflated with the reported net loss. Liquidity is what ultimately funds the next leg of development, and the hefty reserve sits opposite a steady capital requirement. The quarterly guidance is no guarantee of total future funding needs.
Viking Therapeutics at a turning point? This analysis reveals what investors need to know now.
The cash position got a lift from a capital raise and convertible note completed about a month ago, which brought in roughly $575 million gross, or $550 million net. That financing strengthens the available funds without altering the operating reality: Viking still generates no revenue and must bankroll its pipeline on its own balance sheet.
What Investors Should Watch Next
Read the balance sheet and the burn rate as a pair. A $960 million stockpile tells you nothing on its own about how financing needs will evolve before a potential launch, and the average quarterly outflow won't map onto a smooth spending curve either.
The takeaway is that Viking has pushed its late-stage programs forward while the possible market entry remains years out. Until then, trial progress, clinical results, and actual cash consumption will drive the investment case. Lian's 2.5-year horizon makes the waiting period easier to picture — it does not remove the development risk. A trial running to plan is not proof of efficacy, and the later readouts, not enrollment or organizational milestones, are what will ultimately settle the matter.
Ad
Viking Therapeutics Stock: New Analysis - 29 October
Fresh Viking Therapeutics information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
